Nemes Rush Group
RPRX icon

Nemes Rush Group’s Royalty Pharma RPRX Stock Holding History

Nemes Rush Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.17K Hold
20
– – ﹤0.01% 824
2026
Q2 		$1.12K Hold
20
– – ﹤0.01% 853
2026
Q1 		$959 Hold
20
– – ﹤0.01% 826
2025
Q4 		$773 Buy
+20
New +$763 ﹤0.01% 841

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
New South Capital Management
New South Capital Management Memphis, Tennessee $1.53B AUM 36.31% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Nemes Rush Group's RPRX Position: Q3 2026 in Review

Nemes Rush Group held its Royalty Pharma (RPRX) position steady in Q3 2026 at 20 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #824.

Nemes Rush Group first reported a position in RPRX in Q4 2025 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Nemes Rush Group held 20 shares of Royalty Pharma worth $1.17K as of Q3 2026.
  • Nemes Rush Group left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #824 holding.
  • Nemes Rush Group first reported a position in Royalty Pharma in Q4 2025 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.